Aerie Pharmaceuticals Inc (AERI) : Dafna Capital Management scooped up 31,400 additional shares in Aerie Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 179,769 shares of Aerie Pharmaceuticals Inc which is valued at $3,313,143.Aerie Pharmaceuticals Inc makes up approximately 2.62% of Dafna Capital Management’s portfolio.
Other Hedge Funds, Including , Schonfeld Strategic Advisors added AERI to its portfolio by purchasing 11,990 company shares during the most recent quarter which is valued at $220,976. Aerie Pharmaceuticals Inc makes up approx 0.05% of Schonfeld Strategic Advisors’s portfolio. Spark Investment Management sold out all of its stake in AERI during the most recent quarter. The investment firm sold 161,900 shares of AERI which is valued $2,983,817.Mufg Americas Holdings Corp boosted its stake in AERI in the latest quarter, The investment management firm added 225 additional shares and now holds a total of 380 shares of Aerie Pharmaceuticals Inc which is valued at $6,821.Asymmetry Capital Management reduced its stake in AERI by selling 56,561 shares or 40.23% in the most recent quarter. The Hedge Fund company now holds 84,026 shares of AERI which is valued at $1,554,481. Aerie Pharmaceuticals Inc makes up approx 2.66% of Asymmetry Capital Management’s portfolio.
Aerie Pharmaceuticals Inc closed down -0.15 points or -0.77% at $19.21 with 2,92,187 shares getting traded on Thursday. Post opening the session at $19.38, the shares hit an intraday low of $18.84 and an intraday high of $19.53 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on Aerie Pharmaceuticals Inc. Cantor Fitzgerald Resumed Aerie Pharmaceuticals Inc on Jun 3, 2016 to “Buy”, Price Target of the shares are set at $44.
Aerie Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates triple-action Rhopressa and quadruple-action Roclatan are once-daily eye drops. The Company’s product candidate once-daily quadruple-action Roclatan is a single drop fixed-dose combination of Rhopressa and latanoprost. Rhopressa inhibits Rho Kinase (ROCK) and the norepinephrine transporter (NET) which are both biochemical targets for lowering intraocular pressure (IOP). The Company’s Rhopressa product candidate was in Phase III stage of development. The Company has completed the Roclatan Phase IIb clinical trial. The Company is also in the preclinical development stage with AR-13533 its second-generation ROCK/NET inhibitor.